2025
The Impact of Cognitive Impairment on Cardiovascular Disease
Jamil Y, Krishnaswami A, Orkaby A, Stimmel M, Brown Iv C, Mecca A, Forman D, Rich M, Nanna M, Damluji A. The Impact of Cognitive Impairment on Cardiovascular Disease. Journal Of The American College Of Cardiology 2025, 85: 2472-2491. PMID: 40562512, DOI: 10.1016/j.jacc.2025.04.057.Peer-Reviewed Original ResearchConceptsImpact of cognitive impairmentCognitive impairmentCardiovascular diseaseHealth care utilizationOlder adult populationEvidence-based management strategiesMedical adverse eventsHealth literacyCare utilizationOlder adultsMitigate cognitive impairmentUnder-prescribedReduced participationU.S. populationTreatment of patientsAdult populationGuideline-directedExcess morbidityCardiac patientsRisk factorsOlder patientsAdverse eventsHealthMechanism of cognitive impairmentInterventional managementPsychological Aspects of Wearable Health Technologies in Patients with Cardiovascular Disease: A Literature Review and Call to Action
Gaffey A, Hooker S, Lampert R, Gehi A, Rosman L. Psychological Aspects of Wearable Health Technologies in Patients with Cardiovascular Disease: A Literature Review and Call to Action. Current Cardiology Reports 2025, 27: 92. PMID: 40478308, DOI: 10.1007/s11886-025-02234-7.Peer-Reviewed Original ResearchConceptsWearable health technologiesMental healthCardiovascular diseaseHealth technologiesCardiovascular disease self-managementPatients' mental healthAdverse psychological reactionsQuality of lifeProvider burdenHealthy behaviorsHealthcare providersHealthcare utilizationSelf-managementWell-designed prospective studiesCVD managementHealth metricsHealthcare systemHigh-risk groupLifestyle modificationConsumer wearablesImplementation of wearablesPatient outcomesHealthcarePsychological reactionsPsychological effectsThe Brain Care Score and its associations with cardiovascular disease and cancer
Senff J, Rivier C, Tack R, Tan B, Kimball T, Brouwers H, Newhouse A, Fricchione G, Tanzi R, Yechoor N, Chemali Z, Anderson C, Rosand J, Falcone G, Singh S. The Brain Care Score and its associations with cardiovascular disease and cancer. Family Practice 2025, 42: cmaf034. PMID: 40464807, DOI: 10.1093/fampra/cmaf034.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesDementiaDepressionFemaleHumansIncidenceMaleMiddle AgedNeoplasmsProportional Hazards ModelsRisk FactorsUnited KingdomConceptsLate-life depressionIncidence of cardiovascular diseaseCare scoresCardiovascular diseaseUK Biobank (UKBCases of cardiovascular diseaseRisk of dementiaHealth-related behaviorsIncident cardiovascular diseaseModifiable risk factorsCases of cancerCancer typesUKB participantsCox proportional hazards regression analysisProportional hazards regression analysisHazards regression analysisHealthy agingRisk factorsUKBDementiaRegression analysisFollow-upParticipantsAge-related brain diseasesBaselineEffect modification by cardiovascular and metabolic disease onset on long-term PM2.5 exposure and mortality: a nationwide cohort study
Jang H, Park J, Lee E, Kang D, Moon J, Song I, Ahn S, Kim A, Kang C, Oh J, Kwon D, Min J, Kim E, Bell M, Kim H, Lee W. Effect modification by cardiovascular and metabolic disease onset on long-term PM2.5 exposure and mortality: a nationwide cohort study. Scientific Reports 2025, 15: 19570. PMID: 40467860, PMCID: PMC12137577, DOI: 10.1038/s41598-025-04498-z.Peer-Reviewed Original ResearchConceptsLong-term PM2.5 exposureEffect modificationPM2.5 exposureEstimate effect modificationPM2.5-mortality associationsPopulation-representative cohortTarget specific interventionsMyocardial infarctionNationwide cohort studyNon-accidental deathsEffects of PM2.5PM2.5-mortalityRisk of PM2.5Preemptive careCox regression modelsHTN/DMCohort studyHazard ratioDisease onsetCerebrovascular diseaseRegression modelsMetabolic disease onsetCohortRenal diseaseMortalityAccountable Care Organization Participation and Cardiovascular Care Quality
Spatz E, Oddleifson D, Kayani J, Gosch K, Jones P, Doshi R, Maddox T, Desai N. Accountable Care Organization Participation and Cardiovascular Care Quality. JAMA Cardiology 2025, 10: 545-554. PMID: 40172907, PMCID: PMC11966472, DOI: 10.1001/jamacardio.2025.0381.Peer-Reviewed Original ResearchConceptsMedicare Shared Savings ProgramMedicare Shared Savings Program Accountable Care OrganizationsAccountable care organizationsAccountable care organization participationOutpatient cardiology practicesImplantable cardioverter defibrillator useCare qualityDefibrillator useNon-ACO practicesCardiology practiceQuality measuresImprove care qualityPre-post cohort studyPractice participationBlood pressure controlGroup of Medicare beneficiariesShared Savings ProgramCoronary artery diseaseQuality performance scoresAssociated with differential changesTraditional Medicare patientsARB prescriptionCare organizationsAntiplatelet prescriptionArtery disease10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population
Faridi K, Malik D, Essa M, Yang H, Spatz E, Krumholz H, Lu Y. 10-Year and 30-Year Risks of Cardiovascular Disease in the U.S. Population. Journal Of The American College Of Cardiology 2025, 85: 2239-2249. PMID: 40499978, DOI: 10.1016/j.jacc.2025.03.546.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCardiovascular DiseasesFemaleHumansMaleMiddle AgedNutrition SurveysPrevalenceRisk AssessmentRisk FactorsUnited StatesConceptsRisk of cardiovascular diseaseAtherosclerotic CVDU.S. adultsU.S. populationHispanic adultsCardiovascular diseaseCVD riskLong-term riskNational Health and Nutrition Examination SurveyHealth and Nutrition Examination SurveyRisk of atherosclerotic CVDElevated 10-year riskLong-term risk of cardiovascular diseaseAdults aged >Nutrition Examination SurveyTotal cardiovascular diseaseRisk factor profileRisk of total cardiovascular diseaseSurvey-weighted prevalenceMiddle-aged adultsPrevent cardiovascular diseaseHeart failureExamination SurveyAge-standardizedBlack adultsCandidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1
Rosende A, Romero C, DiPette D, Brettler J, Van der Stuyft P, Satheesh G, Perel P, Chapman N, Moran A, Schutte A, Sharman J, Irazola V, Huffman M, Campbell N, Salam A, Lanas F, Coca A, Garcia-Zamora S, Ferreiro A, Lopez-Jaramillo P, Rico-Fontalvo J, Ridley E, Picone D, Flood D, Piñeiro D, Ojeda C, Rodriguez G, Wellmann I, Orias M, Rivera M, Reyes M, Onuma O, Ramroop S, Khan T, Gonzalez Y, Barroso W, Plavnik F, Zuniga E, Grassani A, Tajer C, Zaidel E, Marin M, Cyr-Philbert S, Amorin I, Aguilera M, Bortolotto L, Avezum A, Ribeiro A, Tobe S, Aumala T, Angell S, Lavados P, Martins S, Echeverri A, Jaffe M, Prabhakaran D, Parati G, Zhang X, Rodgers A, Yusuf S, Whelton P, Ordunez P. Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1. Global Heart 2025, 20: 45. PMID: 40454106, PMCID: PMC12124280, DOI: 10.5334/gh.1428.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesHumansHypertensionPrimary Health CareRenal Insufficiency, ChronicConceptsClinical pathwayNon-physician health workersTeam-based careImprove care deliveryReduce care fragmentationPrimary care settingPrimary health settingsCare of hypertensionGlobal Hearts InitiativeCommunity-based screeningEvidence-based interventionsManagement of risk factorsHigher CVD riskLower blood pressure thresholdHigh CVD risk patientsCardiovascular diseaseChronic kidney diseasePhase 1Blood pressure thresholdsHealth equityCare fragmentationHearts InitiativePrimary careCare deliveryHealth settingsLow and high air temperature and cardiovascular risk
Ni W, Areal A, Lechner K, Breitner S, Zhang S, Woeckel M, Slesinski S, Nikolaou N, Dallavalle M, Schikowski T, Schneider A. Low and high air temperature and cardiovascular risk. Atherosclerosis 2025, 406: 119238. PMID: 40383648, DOI: 10.1016/j.atherosclerosis.2025.119238.Peer-Reviewed Original ResearchMeSH KeywordsAir PollutionCardiovascular DiseasesClimate ChangeCold TemperatureHeart Disease Risk FactorsHot TemperatureHumansRisk AssessmentRisk FactorsTemperatureConceptsCardiovascular diseaseArea-level factorsRisk factorsIndividual-level measuresPre-existing cardiovascular diseasePopulation healthCardiovascular healthCardiovascular mortalityPublic healthHealthJ-shapedEpidemiological dataCardiovascular riskBiological plausibilityRiskAir pollutionAssociationPopulationMortalityClimate changeExtremitiesIndividual-Social dimensions of climate changeDiseaseDimensions of climate changeCardiac macrophage: Insights from murine models to translational potential for human studies
Liu Y, Wang T, Lu Y, Riaz M, Qyang Y. Cardiac macrophage: Insights from murine models to translational potential for human studies. Journal Of Molecular And Cellular Cardiology 2025, 204: 17-31. PMID: 40354877, PMCID: PMC12162190, DOI: 10.1016/j.yjmcc.2025.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCardiovascular DiseasesDisease Models, AnimalHumansMacrophagesMiceMyocardiumTranslational Research, BiomedicalConceptsCardiovascular diseaseMurine studiesCardiac macrophagesImmune cellsDisease progressionCardiac homeostasisHuman studiesFunctional significanceCell typesTherapeutic targetCardiac microenvironmentTranslational potentialProgressive pathologyDevelopmental originsPhysiological maintenanceMacrophagesMicroenvironmentMechanical stimuliDiseaseFunctional responseCellsDynamic roleExperimental toolHuman modelLineagesConversion Therapy Exposure and Elevated Cardiovascular Disease Risk
Gibb J, Schrock J, Smith M, D’Aquila R, McDade T, Mustanski B. Conversion Therapy Exposure and Elevated Cardiovascular Disease Risk. JAMA Network Open 2025, 8: e258745. PMID: 40327341, PMCID: PMC12056572, DOI: 10.1001/jamanetworkopen.2025.8745.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCardiovascular DiseasesChicagoCohort StudiesCross-Sectional StudiesFemaleHeart Disease Risk FactorsHumansMaleSexual and Gender MinoritiesYoung AdultConceptsHigh blood pressureSystolic blood pressureDiastolic blood pressureSelf-reported high blood pressureCohort studyCardiovascular health dataCardiovascular health indicatorsSelf-reported hypertensionSGM health disparitiesMental health impactsCardiovascular health consequencesCardiovascular disease riskBlood pressureElevated diastolic blood pressureHealth disparitiesCare approachElevated systolic blood pressureHealth indicatorsMain OutcomesIncreased DBPBehavioral covariatesHealth dataSGM individualsDisease riskHealth consequencesAssociations between education and ideal cardiovascular health metrics across 36 low- and middle-income countries
Zhang Y, Tong G, Ma N, Chen S, Kong Y, Rahmartani L, Aheto J, Kanyike A, Fan P, Ashfikur Rahman M, Mkopi A, Kim R, Karoli P, Niyi J, Zemene M, Zhang L, Cheng F, Lu C, Subramanian S, Geldsetzer P, Qiu Y, Li Z. Associations between education and ideal cardiovascular health metrics across 36 low- and middle-income countries. BMC Medicine 2025, 23: 204. PMID: 40189520, PMCID: PMC11974039, DOI: 10.1186/s12916-025-04032-y.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCardiovascular DiseasesCross-Sectional StudiesDeveloping CountriesEducational StatusFemaleHumansMaleMiddle AgedYoung AdultConceptsIdeal cardiovascular health scoreCardiovascular health scoreCVH metricsMiddle-income countriesEducation levelNo educationCardiovascular healthIdeal cardiovascular health metricsStages of epidemiological transitionCardiovascular health metricsMethodsThis cross-sectional studyIdeal blood pressurePoisson regression modelsHigher education levelLower-middle-income countriesCross-sectional studyAmerican Heart AssociationUpper middle-income countriesVegetable intakeVigorous activityLow-income countriesEpidemiological transitionHealth scoresSurveillance SurveyEquivalent combinationPopulation‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Nanna M, Doan Q, Fabricatore A, Faurby M, Henry A, Houshmand‐Oeregaard A, Levine A, Navar A, Sforzolini T, Toliver J. Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial. Diabetes Obesity And Metabolism 2025, 27: 3442-3452. PMID: 40183412, PMCID: PMC12046440, DOI: 10.1111/dom.16370.Peer-Reviewed Original ResearchConceptsHeart disease eventsRisk of heart diseaseUS adultsDisease eventsFood and Drug AdministrationImpact of semaglutideMedical careNational Health and Nutrition Examination Survey dataHeart diseaseNutrition Examination Survey dataPopulation-based prediction modelSurvey of US adultsCardiovascular diseaseRisk of heart attackFood and Drug Administration indicationsUnited StatesPopulation-level impactUS Food and Drug AdministrationRecurrent CV eventsTrial of patientsAdverse cardiovascular eventsType 2 diabetesAtherosclerotic cardiovascular diseaseHazard ratioInclusion criteriaIs Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas M, Galimberti F, Bunick C. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal Of Drugs In Dermatology 2025, 24: 530-533. PMID: 40327575, DOI: 10.36849/jdd.9049.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesChronic DiseaseDermatitis, AtopicHeterocyclic Compounds, 3-RingHumansIncidenceJanus Kinase 1Janus Kinase InhibitorsVenous ThromboembolismConceptsUPA-treated patientsVenous thromboembolismVenous thromboembolism ratesAdverse cardiovascular eventsChronic inflammatory diseaseAtopic dermatitisMACE rateCardiovascular eventsClinical trialsInflammatory diseasesLong-term MACE rateIncidence rateImpact of upadacitinibPersistent systemic inflammationRisk of cardiovascular diseaseSystemic inflammationAD-related inflammationLower MACEBackground incidence ratesUpadacitinibJAK1 inhibitionPatientsThromboembolismCardiovascular diseaseMACEOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.Peer-Reviewed Original ResearchConceptsOral semaglutideType 2 diabetesAdverse cardiovascular eventsCardiovascular eventsCardiovascular outcomesAdverse cardiovascular events outcomeEffects of oral semaglutidePrimary outcomeMajor adverse cardiovascular events outcomeAdverse event profilePrimary outcome eventNonfatal myocardial infarctionChronic kidney diseaseAtherosclerotic cardiovascular diseaseCardiovascular event outcomesSGLT2i treatmentSGLT2i useReceptor agonistsAdverse eventsPrespecified analysesFollow-upCardiovascular deathRandomized trialsSemaglutideNonfatal strokeCardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.
Lee M, Sattar N, Pop-Busui R, Deanfield J, Emerson S, Inzucchi S, Mann J, Marx N, Mulvagh S, Poulter N, Badve S, Pratley R, Perkovic V, Buse J, McGuire D. Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials. Diabetes Care 2025, 48: 846-859. PMID: 40156846, DOI: 10.2337/dc25-0241.Peer-Reviewed Original ResearchConceptsGlucagon-like peptide 1 receptor agonistsPeptide 1 receptor agonistsComposite kidney outcomeGLP-1RAAll-cause mortalityType 2 diabetesKidney outcomesLong-actingOral formulationOutcome trialsHazard ratioReduced incidence of MACEIncidence rates of MACEIncreased risk of severe hypoglycemiaMeta-analysis of randomized trialsLong-acting GLP-1RASystematic review of PubMedWorsening kidney functionRisk of severe hypoglycemiaIncidence of MACERate of MACEEvaluate renal functionAdverse cardiovascular eventsCardiovascular outcome trialsReview of PubMedOlezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial
Bergmark B, Marston N, Prohaska T, Alexander V, Zimerman A, Moura F, Kang Y, Murphy S, Zhang S, Lu M, Karwatowska-Prokopczuk E, Tsimikas S, Giugliano R, Sabatine M. Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: Rationale and design of the Essence–TIMI 73b trial. American Heart Journal 2025, 286: 116-124. PMID: 40081744, PMCID: PMC12065083, DOI: 10.1016/j.ahj.2025.02.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedApolipoprotein C-IIICardiovascular DiseasesClinical Trials, Phase III as TopicComputed Tomography AngiographyCoronary AngiographyDouble-Blind MethodFemaleHeart Disease Risk FactorsHumansHypertriglyceridemiaMaleMiddle AgedOligonucleotidesOligonucleotides, AntisenseRandomized Controlled Trials as TopicTriglyceridesConceptsCoronary computed tomography angiographyCardiovascular riskTriglyceride levelsModerate hypertriglyceridemiaBaseline coronary computed tomography angiographyPlacebo-controlled phase 3 trialClearance of triglyceride-rich lipoproteinsApoC-IIIBaseline triglyceride levelsBaseline to 6 monthsLipid-lowering therapyAntisense oligonucleotidesNoncalcified coronary plaquesPhase 3 trialComputed tomography angiographyLowering triglyceride levelsIncreased cardiovascular riskElevated cardiovascular riskReduce cardiovascular riskAtherosclerotic cardiovascular diseaseTriglyceride-rich lipoproteinsPotential therapeutic strategyPooled placeboApolipoprotein C-IIIDouble-blindThe burden of cardiovascular disease in Latin America and the Caribbean, 1990-2019: An analysis of the global burden of disease study
Alhuneafat L, Al Ta'ani O, Arriola-Montenegro J, Al-Ajloun Y, Naser A, Chaponan-Lavalle A, Ordaya-Gonzales K, Pertuz G, Maaita A, Jabri A, Altibi A, Al-Abdouh A, Van't Hof J, Gutierrez Bernal A. The burden of cardiovascular disease in Latin America and the Caribbean, 1990-2019: An analysis of the global burden of disease study. International Journal Of Cardiology 2025, 428: 133143. PMID: 40064205, DOI: 10.1016/j.ijcard.2025.133143.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCardiovascular DiseasesCaribbean RegionCost of IllnessFemaleGlobal Burden of DiseaseHumansIncidenceLatin AmericaMaleMiddle AgedPrevalenceRisk FactorsConceptsDisability-adjusted life yearsGlobal Burden of DiseaseBurden of cardiovascular diseaseCardiovascular diseaseRisk factorsMortality-to-incidence ratioGlobal burdenIschemic heart diseaseAge-standardized disability-adjusted life yearsGlobal Burden of Disease StudyDisability-adjusted life year ratesBurden of Disease StudyAge-standardized prevalenceComparative risk assessment frameworkCardiovascular disease prevalenceCardiovascular disease burdenBurden of diseaseLeading risk factorHeart diseaseTailored interventionsCountry-specific variationsElevated BMIRate of strokeHealthcare infrastructureSocio-economic factorsIdentification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
Loesch D, Garg M, Matelska D, Vitsios D, Jiang X, Ritchie S, Sun B, Runz H, Whelan C, Holman R, Mentz R, Moura F, Wiviott S, Sabatine M, Udler M, Gause-Nilsson I, Petrovski S, Oscarsson J, Nag A, Paul D, Inouye M. Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities. Nature Communications 2025, 16: 2124. PMID: 40032831, PMCID: PMC11876343, DOI: 10.1038/s41467-025-56695-z.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCardiovascular DiseasesComorbidityDiabetes Mellitus, Type 2Extracellular Matrix ProteinsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInsulin-Like Growth Factor Binding Protein 2MaleMiddle AgedMultifactorial InheritanceProteomicsRisk FactorsUnited KingdomConceptsPolygenic scoresNon-coding variantsEtiology of type 2 diabetesMolecular dataVariant effectsPathway enrichmentPlasma proteomic markersPotential therapeutic targetType 2 diabetesProteinDisease biologyPolygenic riskUK BiobankProteomic markersTherapeutic targetPathwayCirculating proteinsGenomeRisk of type 2 diabetesCardiometabolic scoreBiologyInteractive portalVariantsEnrichmentDiabetes comorbiditiesEffect of Air Pollution Reductions on Mortality During the COVID-19 Lockdowns in Early 2020.
Chen K, Ma Y, Marb A, Nobile F, Dubrow R, Stafoggia M, Breitner S, Kinney P. Effect of Air Pollution Reductions on Mortality During the COVID-19 Lockdowns in Early 2020. Research Report 2025, 2025: 1-47. PMID: 40551404, PMCID: PMC12185919.Peer-Reviewed Original ResearchMeSH KeywordsAir PollutantsAir PollutionCaliforniaCardiovascular DiseasesChinaCOVID-19Environmental ExposureGermanyHumansItalyMortalityNitrogen DioxideParticulate MatterSARS-CoV-2ConceptsAir pollution changesAir pollutionPollution changesShort-term exposure to PM<sub>2.5</sub>Air qualityExposure to PM<sub>2.5</sub>Natural-causeMeteorological normalization techniqueFine particulate matterDaily air pollutionImprove air qualityAir pollutant emissionsAir pollution reductionEmission control strategiesSouthern ItalyQuantify changesAir pollution-mortality relationshipPollution-mortality relationshipCOVID-19 lockdownShort-term exposureNOParticulate matterMeteorological impactsNitrogen dioxidePollution reductionOptimizing Psychological Health Across the Perinatal Period: An Update on Maternal Cardiovascular Health: A Scientific Statement From the American Heart Association
Sharma G, Gaffey A, Hameed A, Kasparian N, Mauricio R, Marsh E, Beck D, Skowronski J, Wolfe D, Levine G, Research T. Optimizing Psychological Health Across the Perinatal Period: An Update on Maternal Cardiovascular Health: A Scientific Statement From the American Heart Association. Journal Of The American Heart Association 2025, 14: e041369. PMID: 39996493, PMCID: PMC12132617, DOI: 10.1161/jaha.125.041369.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Heart AssociationCardiovascular DiseasesFemaleHumansMaternal HealthMental HealthPerinatal CarePregnancyPregnancy ComplicationsRisk FactorsUnited StatesConceptsMaternal cardiovascular healthPsychological healthCardiovascular healthAmerican Heart AssociationPerinatal periodCare delivery modelsMaternal psychological healthScientific statementPsychological health carePostpartum follow-upHeart AssociationPsychological health conditionsAssociated with adverse pregnancy outcomesCardiovascular outcomesMaternal mortalityAdverse pregnancy outcomesHealth careDelivery modelsHealth conditionsLong-term cardiovascular outcomesHealthStakeholder partnersOffspring neurodevelopmentPregnancy outcomesCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply